

***Alexa Hetzel, PA-C***  
**Ahetzel02@gmail.com**

**APPOINTMENTS/EMPLOYMENT**

*Academic Appointments:*

9/2015-5/2018            Physician Assistant Student, Monmouth University  
9/2017-5/2018            Graduate Assistant, Monmouth University  
8/2008-5/2012            Penn State University, Bachelor of Science in Kinesiology  
8/2011-12/2011           Teaching Assistant  
Fitness with Exercise Physiology

*Employment:*

3/2015-7/2015            Clinical Research Coordinator  
Psoriasis Treatment Center of Central New Jersey  
9/2016-7/2015            Certified Medical Assistant  
Windsor Dermatology, PC

**GAPS IN EMPLOYMENT** *None*

**EDUCATION**

9/2015-5/2018            M.S. in Physician Assistant  
Monmouth University, New Jersey  
8/2008-5/2012            B.S. in Kinesiology  
The Pennsylvania State University, University Park, PA  
9/2004-6/2008            Graduated  
Metuchen High School, Metuchen New Jersey

**CERTIFICATION**

9/2017                      Advanced Life Support  
9/2017                      Basic Life Support  
5/2018                      NCCPA

**LICENSURE**

7/2018                      Physicians Assistant license #**25MP00479400**  
7/2018                      CDS # **A00327500**  
7/2018                      DEA #**MH4870350**

## **HONORS/AWARDS**

2018 Phi Alpha National Honor Society

2009- 2012 Academic All Big Ten

## **MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS**

9/2017- Present New Jersey Society of Physician Assistants

5/206-Present American Academy of Physician Assistants

## **OTHER PROFESSIONAL ROLES**

9/2015-10/2016 Monmouth University Student Society President

## **GRANTS, CONTRACTS, FOUNDATION SUPPORT** *None*

## **RESEARCH PROFILE**

### *Research*

2/2017-5/2018 Utilization of Physician Assistants by Physicians and Pharmacists for their personal use

## **CLINICAL TRIAL PARTICIPATION**

<b><i>Dates</i></b>	<b><i>Project</i></b>	<b><i>Role in Project</i></b>	<b><i>Sponsored by</i></b>	<b><i>Other Info</i></b>
2015	A Phase III, Multi-Center, Double-Blind, Randomized, Vehicle Controlled Clinical Study To Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis	Principal Investigator	Dow Pharmaceutical Sciences	
2015	A Phase III, Multi-Center, Open Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis	Principal Investigator	Dow Pharmaceutical Sciences	
2015	A Multi-Center, Randomized, Double-Blind Study	Principal Investigator	Eli Lilly and Company	

	Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis			
2015	An Open Label Extension Trial Assessing the Safety and Efficacy of BI 655066 Administered Subcutaneously in Patients with Moderate to Severe Chronic Plaque Psoriasis	Principal Investigator	Boehringer Ingelheim Pharmaceuticals, Inc	
2015	A Prospective, Observational, US-Based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed with Mycosis Fungoides Cutaneous T-Cell Lymphoma and Treated with Valchlor	Principal Investigator	Actelion Pharmaceuticals US, Inc	
2015	A Phase IV, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004), in Subjects with Moderate Plaque Psoriasis	Principal Investigator	Celgene Corporation	
2015	An Open-Label Study of Dupilimab in Patients with Atopic Dermatitis who participated in Previous Dupilimab Clinical Trials	Principal Investigator	Regeneron Pharmaceuticals, Inc	
2015	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilimab Dose Regimens	Principal Investigator	Regeneron Pharmaceuticals, Inc	<i>Lancet.</i> 2017 May 4. pii: S0140-6736(17)31191-1. doi: 10.1016/S0140-6736(17)31191-1. [Epub ahead of print] Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised,

	Administered as Monotherapy For Maintaining Treatment Response in Patients with Atopic Dermatitis			double-blinded, placebo-controlled, phase 3 trial. Blauvelt A <sup>1</sup> , de Bruin-Weller M <sup>2</sup> , Gooderham M <sup>3</sup> , Cather JC <sup>4</sup> , Weisman J <sup>5</sup> , Pariser D <sup>6</sup> , Simpson EL <sup>7</sup> , Papp KA <sup>8</sup> , Hong HC <sup>9</sup> , Rubel D <sup>10</sup> , Foley P <sup>11</sup> , Prens E <sup>12</sup> , Griffiths CEM <sup>13</sup> , Etoh T <sup>14</sup> , Pinto PH <sup>15</sup> , Pujol RM <sup>16</sup> , Szepietowski JC <sup>17</sup> , Ettler K <sup>18</sup> , Kemény L <sup>19</sup> , Zhu X <sup>20</sup> , Akinlade B <sup>21</sup> , Hultsch T <sup>22</sup> , Mastey V <sup>21</sup> , Gadkari A <sup>21</sup> , Eckert L <sup>23</sup> , Amin N <sup>21</sup> , Graham NMH <sup>21</sup> , Pirozzi G <sup>24</sup> , Stahl N <sup>21</sup> , Yancopoulos GD <sup>21</sup> , Shumel B <sup>21</sup> .
2015	Single-Center, Two Phase, Pilot Study to Evaluate the Efficacy and Safety of Combining Otezla® (apremilast) 30mg BID in Combination with Narrowband UVB (nUVB) Phototherapy, to Determine Effectiveness of Otezla® in Promoting Maintenance of Response in the Treatment of Moderate-to-Severe Plaque Psoriasis	Principal Investigator	Jerry Bagel, MD	
2015	Randomized, Phase 2, Double-Blind, Vehicle-Controlled Trial to Evaluate the Safety and Efficacy of Q301 Cream in Patients with Moderate to Severe Atopic Dermatitis	Principal Investigator	Qurient	
2014	A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate-To-Severe Atopic Dermatitis	Principal Investigator	Regeneron Pharmaceuticals, Inc	<i>N Engl J Med.</i> 2016 Dec 15;375(24):2335-2348. Epub 2016 Sep 30. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. Simpson EL <sup>1</sup> , Bieber T <sup>1</sup> , Guttman-Yassky E <sup>1</sup> , Beck LA <sup>1</sup> , Blauvelt A <sup>1</sup> , Cork MJ <sup>1</sup> , Silverberg JI <sup>1</sup> , Deleuran M <sup>1</sup> , Kataoka Y <sup>1</sup> , Lacour JP <sup>1</sup> , Kingo K <sup>1</sup> , Worm M <sup>1</sup> , Poulin Y <sup>1</sup> , Wollenberg A <sup>1</sup> , Soo Y <sup>1</sup> , Graham NM <sup>1</sup> , Pirozzi G <sup>1</sup> , Akinlade B <sup>1</sup> , Staudinger H <sup>1</sup> , Mastey V <sup>1</sup> , Eckert L <sup>1</sup> , Gadkari A <sup>1</sup> , Stahl N <sup>1</sup> , Yancopoulos GD <sup>1</sup> , Ardeleanu M <sup>1</sup> ; SOLO 1 and SOLO 2

				Investigators.
2014	A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by A Dose-Blind and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects with Moderate to Severe Chronic Plaque Psoriasis	Principal Investigator	UBC Biopharma, SPRL	<i>Expert Opin Biol Ther.</i> 2017 Mar;17(3):387-394. doi: 10.1080/14712598.2017.1283401. Epub 2017 Feb 6. Certolizumab pegol for the treatment of psoriasis. Campanati A <sup>1</sup> , Benfaremo D <sup>2</sup> , Luchetti MM <sup>2</sup> , Ganzetti G <sup>1</sup> , Gabrielli A <sup>2</sup> , Offidani A <sup>1</sup> .
2014	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-Type Psoriasis	Principal Investigator	Janssen Research & Development, LLC	<i>J Am Acad Dermatol.</i> 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. Blauvelt A <sup>1</sup> , Papp KA <sup>2</sup> , Griffiths CE <sup>3</sup> , Randazzo B <sup>4</sup> , Wasfi Y <sup>5</sup> , Shen YK <sup>5</sup> , Li S <sup>5</sup> , Kimball AB <sup>6</sup> .
2014	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and Assess Safety and Tolerability Up to 24 Weeks in Adult Subjects with Moderate to Severe Scalp Psoriasis	Principal Investigator	Novartis Pharmaceuticals Corporation	<i>J Am Acad Dermatol.</i> 2017 Ahead of pub Jerry Bagel, MD, Kristina Callis Duffin, MD, MS, Angela Moore, MD, Laura K. Ferris, MD, PhD, Kimberly Siu, MD, MPH, Jennifer Steadman, MSW, Farid Kianifard, PhD, Judit Nyirady, MD, MBA, Mark Lebwohl, MD. The Effect of Secukinumab on Moderate-to-Severe Scalp Psoriasis: Results of a 24-Week, Randomized, Double-blind, Placebo-controlled Phase 3b Study.
2014	Characterization of Chronic	Principal Investigator	TRBIO	

	Inflammatory Skin Disease			
2014	A Small Methods Study Involving Electronic Data Collection in Normal Care Settings with Adult Psoriasis Patients Who Have A High Level of Clearance (As Determined by sPGA of 0 or 1) And Are Currently Being Treated With A Biologic	Principal Investigator	HRA	
2014	LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects with Psoriasis Vulgaris	Principal Investigator	Leo Pharma	<i>Skinmed.</i> 2017 Apr 1;15(2):119-124. eCollection 2017. Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies. Menter A <sup>1</sup> , Gold LS <sup>2</sup> , Koo J <sup>3</sup> , Villumsen J <sup>4</sup> , Rosén M <sup>4</sup> , Lebwohl M <sup>5</sup> .
2014	A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis	Principal Investigator	Valeant	
2014	A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects with Chronic Plaque Psoriasis	Principal Investigator	AbbVie	
2014	A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy	Principal Investigator	Novartis	

	as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with Moderate to severe plaque psoriasis			
2014	A 48 weeks study of three different dose regimens of BI 655066 Administered subcutaneously in patients with moderate to severe Chronic plaque psoriasis (randomized, dose-ranging, active-comparator controlled (ustekinumab), double-blind within dose groups of BI 655066	Principal Investigator	Boehringer Ingelheim	<i>N Engl J Med.</i> 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. Papp KA <sup>1</sup> , Blauvelt A <sup>1</sup> , Bukhalo M <sup>1</sup> , Gooderham M <sup>1</sup> , Krueger JG <sup>1</sup> , Lacour JP <sup>1</sup> , Menter A <sup>1</sup> , Philipp S <sup>1</sup> , Sofen H <sup>1</sup> , Tying S <sup>1</sup> , Berner BR <sup>1</sup> , Visvanathan S <sup>1</sup> , Pamulapati C <sup>1</sup> , Bennett N <sup>1</sup> , Flack M <sup>1</sup> , Scholl P <sup>1</sup> , Padula SJ <sup>1</sup> .

## PUBLICATIONS

- 2018 Baron H, Hetzel A, Fixler D, Trujillo B, Tulino J. Utilization of Physician Assistants by Physicians and Pharmacists. May 2018:1-21.
- 2017 Bagel J, Hetzel A. Biologics and Pediatric Psoriasis. *Practical Dermatology*. 2017;14(3):12-13.